Fulgent Genetics, a hybrid genomic diagnostics and biopharma company, reported ongoing expansion of its laboratory testing services alongside increasing R&D investment in its therapeutic nano-drug delivery pipeline. The latest quarterly results highlight operational pressures from billing system transitions impacting collections, but the company maintains strong liquidity with minimal debt. Its proprietary technology platform underpins broad test scalability and cost efficiencies, positioning it competitively amid established peers. Key risks include competitive intensity, reimbursement variability, and clinical development uncertainties, with upcoming milestones focused on clinical trial progression for oncology candidates and completion of billing upgrades.